Lynn Seely hits the exit as Myovant graduates to commercial space — handing the reins to Amgen vet
When Lynn Seely took the helm at Myovant as the newly-retired chief medical officer of Medivation, the biotech was still a fledgling member of Vivek Ramaswamy’s sprawling Vant family, preparing to take flight with a Phase III drug from Takeda. Four and a half years later, everything has changed: Myovant’s largest shareholder is now Japanese pharma Sumitomo Dainippon, and in just the past month, the FDA handed relugolix its first approval and Pfizer has engineered a $4.2 billion commercial partnership.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.